We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration

News   Mar 27, 2015

 
MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration
 
 
Advertisement
 

RELATED ARTICLES

IL-33 Implicated in SARS-CoV-2 Immunity

News

Researchers have unveiled a novel feature of COVID-19 immunity, which could have implications for future therapies. The study points to the involvement of Interleukin 33 when immune cells encounter Sars-CoV-2 for a second time.

READ MORE

Conserved Antibody Binding-Site Identified Across COVID-19 Variants

News

Scientists have uncovered the first full structure of the coronavirus nucleocapsid (N) protein and discovered how antibodies from COVID-19 patients interact with it. They also determined that the structure appears similar across many coronaviruses, including recent COVID-19 variants — making it an ideal target for advanced treatments and vaccines.

READ MORE

Prioritizing Drugs Targeting IFNAR2 and ACE2 To Treat COVID-19

News

Researchers have used human genetics in a new study and the findings suggest researchers should prioritize clinical trials of drugs that target the proteins IFNAR2 and ACE2 to manage COVID-19 in its early stages.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE